CUTE MYELOGENOUS leukemia (AML) is a neoplastic disease arising from the transformation of a single hematopoietic progenitor. The molecular mechanisms underlying this transformation remain poorly understood.' Although effective induction chemotherapy is capable of inducing remission in 60% to 80% of patients, long-term survival is usually only achieved in 25% to 30% of patients.',' There is therefore a need for more effective regimens to prolong the duration of remission and the long-term survival of patients with AML. Recent results elucidating the molecular mechanisms underlying T-cell-tumor cell interactions and T-cell activation and costimulation have revived the possibility that immunotherapy may provide such an approach, leading to more effective tumor rejection and eradication. ',5 Host response to the tumor is dependent on the existence of antigens that can be recognized as foreign by the host immune system. Most of these antigens are not cell surface proteins, but intracellular peptides derived from altered oncogene and suppressor gene products that reach the surface of tumor cells located in a groove of the major histocompati- 
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tic disease arising from the transformation of a single hematopoietic progenitor. The molecular mechanisms underlying this transformation remain poorly understood.' Although effective induction chemotherapy is capable of inducing remission in 60% to 80% of patients, long-term survival is usually only achieved in 25% to 30% of patients.',' There is therefore a need for more effective regimens to prolong the duration of remission and the long-term survival of patients with AML. Recent results elucidating the molecular mechanisms underlying T-cell-tumor cell interactions and T-cell activation and costimulation have revived the possibility that immunotherapy may provide such an approach, leading to more effective tumor rejection and eradication. ',5 Host response to the tumor is dependent on the existence of antigens that can be recognized as foreign by the host immune system. Most of these antigens are not cell surface proteins, but intracellular peptides derived from altered oncogene and suppressor gene products that reach the surface of tumor cells located in a groove of the major histocompatibility (MHC) class I or class I1 molecule^.^^^ Thus, at least some and perhaps most tumor types can be recognized by autologous T cells.* However, there is a plausible explanation for the fact that even tumors that express MHC and rejection antigens can evade destruction by T-cell immunity. Recognition and consequent destruction of immunologic targets by T cells require two cellular signals: ( 1 ) an initial, antigen-specific signal as mediated by the engagement of the T-cell receptor with the antigen-MHC complex, and (2) a second, non-antigen-specific or costimulatory signal, delivered by accessory receptors following their engagement by ligands expressed on antigen-presenting cells (APCs).'" The presence or absence of the costimulatory signals determines whether the T-cell receptor complex engagement leads to T-cell clonal expansion and induction of effector functions or to an antigenspecific state of unresponsiveness (anergy).""'
The most extensively studied costimulatory pathway involves the interaction of the T-cell receptors CD28 and CTLA-4 with the B7 family ligands (B7-1 and B7-2) expressed on APCs, which appears to provide the major costimulatory signal for T-cell activation.'"'" The importance of the discovery of the B7/CD28 pathway for tumor immunology lies in the fact that most tumors are derived from parenchymal or mesenchymal cells that do not express B7." It was thus speculated that introduction of the B7 gene into tumors might result in effective costimulation and tumor immunogenicity in the immunocompetent host. Indeed, recent studies have demonstrated that transplantable tumor cells transfected with the B7-I gene are rejected in syngeneic All these studies have been based on solid-tumor models, and only very recently Matulonis et al" reported results on a murine leukemia model.
In all tumor models studied so far, B7 expression has been achieved by transduction of transformed tumor cell lines. However, cell lines may acquire cell culture-specific molecular events that then provide different properties to subclones not present in the parental cell line. Because immunotherapeutic vaccines in humans rely on the use of patients' primary tumor cells, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the B7-I cDNA and subsequently used as vaccines. Here. we report the results from these studies, which clearly show that B7-transduced and irradiated primary leukemic cells 
MATERIALS AND METHODS
Mice.
Female SJL/J mice aged 6 to 8 weeks were purchased from Jackson Laboratories (Bar Harbor, ME) and Swiss nu/nu mice from Taconic Laboratories (Germantown, NY). The mice were injected in the tail vein with AML cells, and blood was collected from the orbital sinus in weekly intervals under general anesthesia.
AML cells. AML cells, kindly provided by Shimon Slavin (Hadassa Medical School, Jerusalem, Israel), were originally obtained from radiation-induced AML in female SJWJ mice. 24 We maintained the AML cells by growing them in syngeneic SJWJ mice. In all experiments, freshly isolated or frozen spleen mononuclear cells from leukemic mice (4 to S weeks after the tumor inoculation) were used. Flow cytometry demonstrated that these cells were essentially 100% myeloblasts.
Celf lines. The E-86 ecotropic packaging cell linez5 has been used for generating the virus-producing clones. The cells were maintained in vitro at 37°C in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 2% glutamine, and 1% penicillinstreptomycin.
Retroviral construct.
We generated two retroviral constructs, LNCX-B7-sense and LNCX-B7-antisense, consisting of the fulllength murine B7-I cDNA (DNAX, Palo Alto, CA) subcloned in sense and antisense orientation at the HpaI unique cloning site of the LNCX" retroviral vector, kindly provided by Dusty Miller (Fred Hutchinson Cancer Research Center, Seattle, WA). The LNCX-B7-antisense vector was used for preparation of mock viruses. We transfected the retroviral constructs into the helper-free ecotropic packaging cell line E-86 by calcium phosphate precipitation, and isolated colonies by G41 8 selection (1 mg/mL effective drug concentration). Supernatant from B7-sense and B7-antisense clones secreting virus with a titer of approximately lo5 neocolony-forming U/ mL was used to infect fresh E-86 cells. Two new clones (B7-1-sense and B7-l-antisense), secreting a higher titer of virus (>IO6 neocolony-forming UlmL) were isolated by G418 selection (1 mg/ mL) and used for infection of AML cells.
Northern and Southern blot hybridizations. Total cellular RNA was extracted from spleen AML cells and control cell lines using the guanidinium isothiocyanate procedure for Northern blot hybridi~ation.'~ Ten micrograms of RNA was electrophoresed on a 2.2-molL formaldehyde-1.5% agarose gel, transferred to a nylon filter (Hybond-N; Amersham, Arlington Heights, IL), and hybridized with a PstI 1,448-bp fragment from the murine myeloperoxidase cDNA, kindly provided by Bernard Matbey-Prevot (Dana-Farber Cancer Institute). High-molecular-weight DNA was prepared from E-86 cells and B7-l-sense and -antisense clones using standard techniques for Southern blot hybridization." Ten micrograms of DNA was digested with restriction enzymes, electrophoresed on a 0.7% agarose gel, and transferred to a nylon filter (Hybond-N). The filters were probed with the [a-"P]dCTP-labeled, random-primed BamHVXbal fragment from the LNCX vector (nucleotides 2,797 to 3,963, which include sequences of the Neo resistance gene, the entire cytomegalovirus promoter, and 3' LTR sequences). Following hybridization, Northern and Southern blots were washed and exposed to Reflexion x-ray film with an intensifying screen (New England Nuclear, Boston, MA) for 24 to 72 hours at -70°C.
Infection ofAML cells. Producer clones secreting a high titer of virus (> 10' colony-forming U/mL) were used for infection of AML cells. Virus-containing medium was harvested from virus-producing cell lines reseeded 24 hours previously without G418 selection, and passed through a 0.45-pm filter (Costar, Cambridge, MA). AML cells (10'/mL) were exposed to viral supernatant in the presence of 8 pg/mL Polybrene and 15% WEHI-3B-conditioned media for 6 to 8 hours, after which 2 v01 medium was added and the cells were incubated for a further 24 hours. These infected, unselected cells were washed in phosphate-buffered saline (PBS) and counted, and the designated number of cells was used for in vivo injections.
Immunostaining and $ow cytometry analysis. Cells were incubated for 30 minutes at 4°C with fluorescein isothiocyanate (FITC)-or phycoerythrin-conjugated monoclonal antibodies (MoAbs) for direct staining. For indirect staining, cells were incubated under the same conditions with the primary MoAb, washed twice with cold PBS, and incubated for a further 30 minutes with FITC-or phycoerythrin-conjugated secondary antibody. The following antibodies were used in our study: CD80 (B7-l), (3-1, CD3-e, CD4 (L3T4), CD8a (Ly-2), CD28, CD22 (Lyb-8.2), and B7-2 (GLI) (Pharmigen, San Diego, CA). For MHC class I antigens, the 15-1-SP MoAb was used (anti-K 'Dk, cross-reacts with D ) , kindly provided by Ellis Reinherz (Dana-Farber Cancer Institute), and for MHC class I1 antigens, the anti-LAh KH74 MoAb (Pharmigen) was used (cross-reacts with I-K). After staining, the cells were fixed in 2% paraformaldehyde and analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
I n vivo immunization studies. SJL/J mice were injected intravenously (IV) with live or irradiated (3,200 rad from a '37Cs source) transduced AML cells. In most of the experiments, 10' B7-l-sense or -antisense infected cells were used, diluted in 200 to 300 pL 1 X PBS.
In vivo T-cell depletions. For in vivo depletion experiments, mice were injected on 3 consecutive days with purified ascites preparations of hybridoma S3.67229 (0.5 mg per injection), producing rat antimouse CD8 MoAb (ATCC, TIB #105), or hybridoma GK1.S'" (0.2 mg per injection), producing rat antimouse CD4 MoAb (ATCC, TIB #207). Mice in the control group were injected with 1 X PBS. One mouse per group was killed 3 days after the last injection, and cells from peripheral blood and spleen were stained with MoAbs to lymphoid antigens. To exclude the possibility that flow cytometry results were due to epitope masking, cells were also stained with an FITC-conjugated goat antirat IgG antibody (CALTAG, San Francisco, CA), which would detect any residual cells of the depleted T-cell population. FACS analysis of stained cells showed that greater than 95% of the relevant population of T cells were depleted, whereas all other subsets remained within normal levels (data not shown). Three days after the last injection, the mice were challenged IV with live B7-l-sense infected AML cells and antibody injections continued every S days for 4 weeks.
In vivo treatment with CTLA-4 Ig. For these experiments, we used the nonlytic murine CTLA-4Fcy2a heavy-chain (mCTLA-4/ Fc) chimeric fusion protein." SJL/J mice were injected intraperitoneally with 100 pg CTLA-4ng and then inoculated the next day with IO5 B7-sense cells admixed with the same amount of protein. Treatment with CTLA-4/Ig every 3 days continued for 4 weeks (the time required for clinically overt leukemia to develop in the mice). Control mice received the same amount of IgG2a as an isotype control.
RESULTS
Clinical and laboratory evaluation of the SJUJ AML model. In all our experiments, freshly isolated or frozen spleen mononuclear cells from leukemic mice (4 to 5 weeks after tumor inoculation) were used. Histochemical staining (data not shown) and Northern blot hybridization showed that these cells express the myeloid differentiation-specific enzyme, myeloperoxidase (Fig l A) . Immunostaining and flow cytometry using the Gr-l myeloid differentiation antigen as a phenotypic marker (not found on lymphoid or erythroid cells) demonstrated that these cells are essentially use only. 1 0 0 % myeloid cells (Fig IB) . AML cells express MHC class I antigens and the CD3 €-chain, but lack MHC class I1 antigens and B?-I , B7-2, CD28, CD4, CD8, and CD22 expression (data not shown).
When spleen AML cells are injected 1V into syngeneic SJLIJ mice, the mice develop leukemia and die in approximately 4 to S weeks, with dissemination of blasts in the peripheral blood, bone marrow, and spleen. White blood cell counts remain within normal limits (10 to 12 X 10"/L) until the middle of the fourth week, after which the peripheral smear shows rapidly increased white blood cell counts up to IS0 to 200 X IO"/L, consisting of essentially 100% myeloblasts. Two virus-producing clones (B7-I -sense and B7-I -antisense) were used for infection of AML cells. Southern blot analysis using a BamHI/Xbal LNCX vector fragment as a probe showed that both clones had integrated LNCX vector-specific sequences, whereas untransfected 5 8 6 cells had not (data not shown). B7-I expression on infected, unselected AML cells was confirmed by surface staining 24 hours after infection. Immunofluorescence staining and flow cytometry clearly demonstrated a homogeneous population expressing B7-I for AML cells infected with B7-l-sense clones (sense AML cells , Fig 2A) , in contrast to the negative, B7-l-antisenseinfected AML cells (antisense AML cells, Fig 2B) . Both unselected sense and antisense AML cells were used for the immunizations.
B7-I exprcssior~ reritm~s tlw tw~~origcnicih (f wild-tye
AML cells. To examine whether B7-1 expression enhances T-cell immunity against otherwise lethal AML cells. we immunized groups of SJL/J mice 1V with 10' to 10" sense or antisense AML cells and determined the clinical outcome. All mice injected with antisense AML cells developed leukemia and died after 4 to S weeks, whereas 100% of the mice injected with IO' to S X IO5 sense AML cells rejected the tumors and remained alive and tumor-free for more than 6 months (Fig 3A) . White blood cell counts from the surviving mice were always within normal ranges. Mice injected with 10" B7-l-sense AML cells had a prolonged survival. but they a l l died of leukemia 1 I to 12 weeks after the immunization (Fig 3B) .
t37-I-trcrnsd1rced AML cdls are t~tmorigcnic irt intmltnocic$cient ( 1 1 t h 1 ) mice. To confirm that 10' to S X 10' transduced sense AML cells were still leukemogenic, Swiss nu/nu mice were injected with sense or antisense AML cells. Retroviral infection of the cells did not impair their growth. and both sense and antisense infected cells were equally as tumorigenic as wild-type cells. All mice in this experiment died 4 to S weeks after tumor inoculation (data not shown). Irrcrrlicrtc4 R7-scnsc~ hut not -c~ntiserl.se AML cells c m incl~tce .sy.stemic antitumor i n l m~t r t i h . We next sought to determine whether the immunity provided by B7-l -expressing AML cells could protect the mice from subsequent challenge with wild-type AML cells. Because the use of irradiated rather than live tumor cells a s vaccines is important for future clinical trials in patients. we examined whether irradiated sense or antisense AML cells were able to induce systemic antitumor immunity. In this set of experiments. mice were use only. (Fig 4) . This protection was long-lasting. since recholl u g e of the same mice S months later with I O ' wild-type AML cells did not induce growth of leukemia and the mice remained tumor-free (data not shown).
For personal
Ecrrly irllr?lrrrli,7crtiorl with irrdicrtcd R7-I --trcrrl.wIrtwd A M L cells rcwt1t.s irl l e l t k m l i t r rejection. Recause tumor vaccines will be used in patients who have established 111-mors, it was of critical importance to determine the role of B7-I -expressing AMI, cells in mice that had been formerly exposed to the AML cells. In these experiments. mice were inoculated with I O ' live wild-type cells and 21 week later immunized with I O ' irradiated sense or antisense cells. Mice immunized with irradiated R7-1 sense AML cells rejected the leukemic cells, whereas all control mice developed leukemia at the expected interval and died (Fig S) .
h t e 11?7,c.rirlrrllltrli,crtiorl of Icwkenric. mice wit11 R7-I -pasi t i w A M L c d l s hrrs (1 prrrtirrl protcwiw c;ffi'c.t.
In these experiments, mice were in.jected with IO5 AML cells and vaccinated after week 2. as opposed to week I , with irradiated I O ' sense or antisense AML cells. Mice vaccinated with irradiated sense cells showed prolonged survival for only 2 to 3 weeks heyond that of the control grot~p (data not shown).
To investigate if hyperimmunization could improve survival. mice were inoculated with 10' AML cells and 2 weeks later immunized once weekly for 3 consecutive weeks with 10' irradiated sense AML cells. The control group received the same number of irradiated antisense cells. Hyperimmunization did not improve survival as compared with that provided by a single in.jection of the mice. which a l l died 2 to 3 weeks later than mice in the control group (Fig 6) . The same experiment was repeated with live (instead of irradiated) sense or antisense cells. with the same results (data not shown). This observation indicated that although the mice do not develop leukemic white blood cell counts above 20 X IO"/ L until late during the fourth week after tumor inoculation, there must be a large leukemic burden as early as the second week. This leukemic burden is sufficiently large that late vaccination of mice cannot generate a sufficient antileukemic immune response. By staining the bone marrow. spleen, and peripheral blood cells with the Gr-l MoAb at weekly intervals after the injection of leukemic cells and comparing the results with data from normal mice, we confirmed that as early as 1 week after AML injection, the percentage of AML blasts as indicated by GR-I-positive cells is dramatically increased in the bone marrow and spleen (Fig 7) .
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Antigen recognition OR the leukemic cells and s~thseqrrent lelrkemia rejection are R7-I -dependent. To investigate if the rejection of B7-l -expressing AML cells is a B7-ldependent immune response, we used the murine CTLA-4/ Ig fusion protein to block the B7/CD28 interaction in vivo.
There is only one published study. by Chen et al.Ix that confirms that the rejection of B7-positive (B7') tumor cells is a B7-mediated immune response.
In our experiments. mice were injected with CTLA-4/lg or IgG2a. as described earlier. The clinical status of the mice was determined daily, and the white blood cell count was monitored once weekly. Mice treated with the CTLA-4/Ig protein developed leukemia and died after S to 6 weeks, whereas mice treated with control Ig rejected B7-expressing leukemic cells and survived tumor inoculation (Fig 8) .
Tlrmor rejection is CDB' hut not CD4' T-cell-dependent.
Studies based on the introduction of B7 into tumors have shown that under appropriate conditions, coexpression of B7 can stimulate both CD4' and CD8' T In these models. tumor cells express both MHC class I and 11 antigens. AML cells in our model do not express MHC class I1 molecules. and therefore. the unknown tumor antigen(s) can only be presented by them in the context of class I molecules. To delineate the role of T-cell subsets in this model. we inoculated B7-transduced AML cells into mice depleted in vivo of CD4' or CD8' T cells. Mice treated with the MoAb GKI .S or I X PBS rejected B7-1 ' AML cells and survived tumor inoculation. In contrast. the depletion of CD8' T cells completely abrogated the rejection of B7-I AML cells. and the mice developed lethal leukemia (Fig 9) . 
DISCUSSION
In this report, we have presented results that show murine primary AML cells are capable of generating tumor-specific immunity when transduced with the B7-1 costimulatory molecule and injected into syngeneic hosts. Our studies have been motivated by the need for new therapeutic modalities in AML and by three relatively recent discoveries in tumor immunology. One is the demonstration that human and animal cancers harbor a variety of tumor-specific mutant proteins that may be recognized as tumor-specific antigen^:""^ The second is the discovery that T cells, including cytolytic T lymphocytes, are able to recognize intracellular mutant proteins by detecting peptides of these proteins presented by MHC molecules on the surface of cells. 35 .'" The third is the A second important difference in our model. especially with regard to future clinical trials. is the potency of irradiated rather than live B7' AML cells to generate immunotherapeutic responses. In three of the previously reported murine tumor models. irradiation of tumor cells transfected with R7 decreased their vaccination Thus. it was speculated that irradiation may have a deleterious effect on tumor cells exploiting the B7/CD28 interaction to generate antitumor immunity." The underlying mechanism of our result is most probably related to specific properties of the primary AML cells used in this model. Nevertheless, it emphasizes the important fact that irradiation does not necessarily abrogate the ability of B7-transduced tumor cells to generate beneficial immune responses.
We have shown that murine primary AML cells can be effectively transduced with the B7-I cDNA, and that virtually 100% of unselected cells show a high level of B7-I expression by FACS analysis. The ability of transduced B7' AML cells to generate antitumor immunity leading to leukemia rejection by naive mice was dose-dependent, since injecrejection.lx-?3.'x However, important differences distinguish tion with 10" cells resulted only in prolonged survival, whereas immunization with 10" to S X IO3 cells led to rejection of the leukemic cells. One might be tempted to argue that this cell dose-dependency results from injection of a presumably higher number of uninfected wild-type cells when using higher cell dosages. However, this is not supported by the observation of a similar dose-dependent beneficial effect when drug-selected cell lines expressing B7 were used as vaccines.'3 A more reasonable explanation is that the cell dose-dependency results from exceeding the ability and/or number of lymphocytes capable of rejecting leukemic cells. This is supported by our observation that the therapeutic effect of vaccinations in leukemic mice was tumor loaddependent: ie, the vaccines were effective only in the early stages of disease. This result. which is consistent with previous indicates that an immune system already exposed to tumor antigen(s). and hence an unresponsive immune system, is still capable of generating a significant but limited number of tumor-specific cytotoxic T-lymphocytes (CTLs) when a B7 costimulatory signal is provided.
Reversal of the unresponsiveness to AML cells after stimulating the B7/CD2X costimulatory pathway could be due to the existence of nonanergic CTL precursors that then give rise to tumor-specific T-cell clones, and/or to a reversal of the anergic state by stimulation with B7' AML cells. It has been demonstrated in tumor models that anergy can be reversed by addition of interleukin-2 (IL-2). even after its full induction. although four or more cell cycles are required for complete Furthermore, data from animal models suggest that CTLs require a relatively low dose of 1L-2 as compared with the toxic high-dose regimens exploiting the lymphokine- Weeks post AML cells injection use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From immune mechanism(s) underlies the reversal of tumor unresponsiveness after the B7/CD28 costimulatory pathway is provided, the number of tumor-specific CTLs is high enough to reject the tumor cells only in the early stages of the leukemia.
It should be noted that T cells from chronic tumor-bearing mice and cancer patients have functional (ie, decreased CTL and signal transduction abn~rmalities.~' There is no information as yet on whether the observed T-cell abnormalities and the possible return to normal function by removal or treatment of the will affect the outcome of tumor vaccines (such experiments are currently under way in our laboratory). One might be tempted to use the data on T-cell alterations to argue that the inability of vaccinations in later stages of the leukemia to provide antitumor immunity is attributable to "deficient" T cells. However, the same results have been observed in a tumor model with a relatively short clinical course of 2 weeks.23 Thus, T-cell alterations due to longer exposure to tumor cells would appear to be the less likely cause of the observed abrogation of protective immunity in later stages of the disease.
The critical demonstration that the effective tumor-specific immune response in our AML model is mediated by the interaction of B7 with its ligands was provided by experiments in which mice were treated in vivo with the CTLA-4 Ig fusion protein. To our knowledge, only in one report has it been shown that rejection of B7' tumor cells is mediated by interactions between B7 and its ligands, CD28 and CTLA-4."
The nature of the tumor antigen(s) in our model is unknown. Immunization and challenge experiments show that one injection with irradiated wild-type AML cells cannot provide protection against subsequent challenge with live AML cells. This outcome suggests that (1) the tumor antigens are not secreted as soluble tumor peptides and hence are not available for uptake by "professional" APCs that constitutively express costimulatory molecules such as the B7-1 antigen; and ( 2 ) the antigens are not presented in the form of peptides on AML cells by MHC molecules in close proximity to professional APCs (trurzs-co~timulation).~~~~~ This assumption is also supported by the in vivo depletion experiments showing that antitumor immunity is CD8' Tcell-dependent, but not CD4' T-cell-dependent. Since AML cells in this model do not express detectable MHC class I1 antigens by flow cytometry, CD4+ T cells can only recognize the tumor antigens if they are presented by professional "bystander" APCs expressing MHC class I1 molecules." Results of the immunization and depletion experiments strongly suggest that tumor antigens are not secreted as soluble tumor peptides, and that they are most probably presented only to CD8+ T cells in the context of MHC class I molecules. It has been previously reported that on tumor models expressing MHC class I1 molecules, either CD8' T CD4' T cells,20 or both T-cell subsets49 were pivotal in the B7-dependent cell-mediated destruction of the tumor. Therefore, it still remains to be determined what specific roles the tumor antigens and the MHC molecules play in generating effector cells.
Because the molecular nature of the rejection antigen(s) on AML cells is not known, it has been a concern that these antigens may have cross-reactivity with epitopes on other hematopoietic progenitors." If this were the case, any type of cross-reactivity would lead to immune recognition and subsequent destruction of normal hematopoietic progenitors, resulting in bone marrow aplasia and peripheral cytopenia. The long-term survival and the normal hematologic parameters of mice that rejected AML cells in our model do not support this scenario.
In conclusion, results from the experimental system described in this report demonstrate that B7 expression renders primary, unselected, and irradiated AML cells capable of effective antigen presentation, which is mediated by B71 CD28 interaction and is CD8' T-cell-dependent. The generated immune responses lead to eradication of B7' AML cells in naive mice and to rejection of already established leukemia in leukemic mice in the early stages of disease. Results from the murine AML model and our preliminary data showing that human AML cells do not express B7-1 provide hope that the same type of vaccination may be the subject of future clinical trials in patients with AML.
